Adaptimmune stock plunges after announcing Nasdaq delisting plans
Investing.com - H.C. Wainwright has reiterated its Buy rating and $60.00 price target on Structure Therapeutics (NASDAQ:GPCR), highlighting the company’s position in the oral weight loss drug market. The stock, currently valued at $1.38 billion, has shown strong momentum with a 10.9% gain over the past week. According to InvestingPro data, the company maintains a solid balance sheet with more cash than debt.
The firm points to Structure’s aleniglipron as standing out among competitors with its robust early weight loss results of approximately 6-7% at 12 weeks and what it describes as best-in-class gastrointestinal tolerability through a low-and-slow titration approach.
H.C. Wainwright notes aleniglipron’s advantages include once-daily oral dosing without food restrictions and a clean hepatic safety profile, with less than 25% of patients experiencing nausea and fewer than 5% discontinuing treatment.
The analysis comes in the context of Eli Lilly’s orforglipron data showing 12.4% mean weight loss at its highest dose but with gastrointestinal-related dropouts in up to one-third of patients, creating what the firm sees as an opportunity for Structure’s potentially more tolerable alternative.
The firm also referenced the recent Pfizer-Metsera deal, suggesting it demonstrates industry appetite for differentiated oral incretin therapies and potential combinations, which could position Structure Therapeutics favorably for future acquisition interest.
In other recent news, Structure Therapeutics has been the focus of several analyst evaluations. Cantor Fitzgerald reiterated its Overweight rating with a price target of $65.00, highlighting the potential performance parallels between Structure Therapeutics’ aleniglipron and Eli Lilly’s orforglipron due to their similar chemical structures. JMP Securities also maintained its Market Outperform rating, setting a price target of $87.00, following positive safety data published in the New England Journal of Medicine. The publication noted that orforglipron did not show a liver safety signal, which is favorable for aleniglipron.
Guggenheim adjusted its price target to $90.00 from $92.00 while maintaining a Buy rating, noting that Structure Therapeutics reaffirmed its timeline for the Phase 2b ACCESS trials, with results expected by the end of 2025. Additionally, JMP Securities slightly lowered its price target to $87.00 from $89.00, expecting a potential stock movement when Eli Lilly presents its Phase 3 non-diabetic data for orforglipron at an upcoming conference. These developments highlight the ongoing interest and analysis surrounding Structure Therapeutics’ drug candidate and its anticipated progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.